Ex-'King of Biotech' set to serve four-year term for fraud

NEW YORK Tue Jan 21, 2014 11:39pm IST

Related Topics

Stocks

   

NEW YORK (Reuters) - David Blech, once dubbed the "King of Biotech", failed to persuade a U.S. appeals court to throw out his four-year prison term for securities fraud on the ground that his sentencing judge was biased.

Blech, 58, had argued in court papers that U.S. District Judge Colleen McMahon improperly considered his race and social status in imposing the sentence.

The defendant, who is white, Jewish and was once among the wealthiest Americans, said McMahon wanted to counter a view that "we let people like you get away with things that we don't let poor black drug addicts" get away with.

In an order on Tuesday, the 2nd U.S. Circuit Court of Appeals said McMahon "made a number of ill‐conceived remarks that bordered on the inappropriate," but that it was not persuaded that she sentenced Blech "based on unconstitutional factors such as race".

It said McMahon sentenced Blech based on factors including "the need for specific deterrence for a recidivist, and the need for general deterrence for those who might otherwise feel that some white‐collar crimes are 'games worth playing.'"

The court also upheld McMahon's $1.34 million forfeiture order, saying Blech waited too long to object.

Richard Levitt, a lawyer for Blech, declined to comment. The defendant had sought to be resentenced by a different judge.

Blech, who has said he has bipolar disorder, had pleaded guilty in May 2012 to manipulating shares of biopharmaceutical companies Pluristem Therapeutics Inc (PSTI.O) and Intellect Neurosciences Inc (ILNS.PK) in 2007 and 2008.

He reached a $1.03 million civil settlement last August with the U.S. Securities and Exchange Commission.

Blech had also pleaded guilty in 1998 to an unrelated fraud, but was sentenced to probation.

Earlier in his career, Blech helped found Celgene Corp (CELG.O), whose products include the blood cancer drug Revlimid, and whose market value on Friday topped $68 billion.

He also helped found Icos Corp, now part of Eli Lilly & Co (LLY.N), which developed Cialis to treat erectile dysfunction.

Forbes magazine said Blech was worth $295 million in 1992, making him among the 400 richest Americans.

Blech is housed at a low-security prison in Fort Dix, New Jersey. He is not eligible for release until March 12, 2017.

The case is U.S. v. Blech, 2nd U.S. Circuit Court of Appeals, No. 13-1881.

(Reporting by Jonathan Stempel; Editing by Stephen Powell)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Literary Giant Dies

Literary Giant Dies

Nobel winner Garcia Marquez, master of magical realism, dies at 87.  Read 

Election 2014

Election 2014

India holds biggest day of voting with BJP gaining strength  Full Article | Full Coverage 

Insider Trading

Insider Trading

Ex-Goldman director Gupta starts prison term on June 17.  Full Article 

Market Eye

Market Eye

Sensex jumps 351 points, snaps 3-day losing streak  Full Article 

Expansion Plans

Expansion Plans

Reliance Industries, HPCL Mittal plan refinery expansions.  Full Article 

S&P on India

S&P on India

S&P: India's ratings to depend on next govt econ, fiscal policies.  Full Article 

Ambitious Aim

Ambitious Aim

In green car race, Toyota adds muscle with fuel-cell launch.  Full Article 

Deal Talk

Deal Talk

Piramal to buy 20 percent stake in Shriram Capital for $334 million.  Full Article 

Bond Market

Bond Market

A star abroad, RBI boss riles bond traders at home  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage